MDS risk higher in patients receiving PARPi for solid tumors

Key clinical point: Among patients with a solid tumor, the use of poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi) was associated with an increased incidence of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in those receiving a PARPi early in their disease course.

Major finding: Use of PARPi was associated with an increased incidence of MDS/AML in the frontline setting (incidence rate ratio [IRR], 5.43; 95% confidence interval [CI], 1.51–19.60) but not in the recurrent setting.

Study details: Findings are from a meta-analysis of 14 phase 2 and 3 clinical trials that randomly allocated 5,739 patients with solid tumors to either PARPi or control therapy.

Disclosures: This study was supported by the National Institutes of Health, National Cancer Institute, and National Center for Advancing Translational Sciences. Some of the authors declared receiving research funding, grants, and/or personal fees from various pharmaceutical companies.

Source: Nitecki R et al. Gynecol Oncol. 2021 Mar 15. doi: 10.1016/j.ygyno.2021.03.011.

Key clinical point: Among patients with a solid tumor, the use of poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi) was associated with an increased incidence of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in those receiving a PARPi early in their disease course.

Major finding: Use of PARPi was associated with an increased incidence of MDS/AML in the frontline setting (incidence rate ratio [IRR], 5.43; 95% confidence interval [CI], 1.51–19.60) but not in the recurrent setting.

Study details: Findings are from a meta-analysis of 14 phase 2 and 3 clinical trials that randomly allocated 5,739 patients with solid tumors to either PARPi or control therapy.

Disclosures: This study was supported by the National Institutes of Health, National Cancer Institute, and National Center for Advancing Translational Sciences. Some of the authors declared receiving research funding, grants, and/or personal fees from various pharmaceutical companies.

Source: Nitecki R et al. Gynecol Oncol. 2021 Mar 15. doi: 10.1016/j.ygyno.2021.03.011.

Key clinical point: Among patients with a solid tumor, the use of poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi) was associated with an increased incidence of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in those receiving a PARPi early in their disease course.

Major finding: Use of PARPi was associated with an increased incidence of MDS/AML in the frontline setting (incidence rate ratio [IRR], 5.43; 95% confidence interval [CI], 1.51–19.60) but not in the recurrent setting.

Study details: Findings are from a meta-analysis of 14 phase 2 and 3 clinical trials that randomly allocated 5,739 patients with solid tumors to either PARPi or control therapy.

Disclosures: This study was supported by the National Institutes of Health, National Cancer Institute, and National Center for Advancing Translational Sciences. Some of the authors declared receiving research funding, grants, and/or personal fees from various pharmaceutical companies.

Source: Nitecki R et al. Gynecol Oncol. 2021 Mar 15. doi: 10.1016/j.ygyno.2021.03.011.